74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Zimmer Biomet Holdings Inc
Closed
SectorHealthcare
101.44 1.91
Overview
Share price change
24h
Min
98.91
Max
101.5
Income | -9.1M 240M |
|---|---|
Sales | 199M 2B |
P/E Sector Avg | 21.709 57.333 |
EPS | 2.31 |
Dividend yield | 1 |
Profit margin | 11.867 |
Employees | 17,000 |
EBITDA | 82M 615M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +19.21% upside |
Dividend yield Sector Avg | 1.00% 2.63% |
|---|---|
Next Earnings | 5 May 2025 |
Next Dividend date | 30 Apr 2025 |
Next Ex Dividend date | 25 Jun 2025 |
Market Cap | -3.1B 19B |
|---|---|
Previous open | 99.53 |
Previous close | 101.44 |
Technical Score
By Trading Central
Confidence
Bullish Evidence
Zimmer Biomet Holdings Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Zimmer Biomet Holdings Inc Forecast
Price Target
By TipRanks
19.21% upside
12 Months Forecast
Average 121 USD 19.21%
High 140 USD
Low 107 USD
Based on 17 Wall Street analysts offering 12 month price targets forZimmer Biomet Holdings Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Zimmer Biomet Holdings Inc
Zimmer Biomet Holdings, Inc. is a global medical technology company. Its segments include Americas, EMEA, and Asia Pacific. The Company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic (CMFT) products; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its other product category primarily includes its robotic, surgical and bone cement products. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee, and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System, and G7 Acetabular System. Its S.E.T. product category includes sports medicine, biologics, foot and others.
